Northwest Biotherapeutics, Inc. (NWBO)
-NasdaqCM | Prev Close: | 3.58 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 4.40 |
|---|
| Beta: | 3.39 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.98 - 20.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 160,008 |
|---|
| Market Cap: | 107.78M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -4.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Can Green Mountain Coffee and 4 Biotechs Climb?at Barrons.com(Mon, Jun 17)
- Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughsat Minyanville(Mon, Jun 17)
- 4 Healthcare Stock Stories Getting Notice On Thursdayat Wall St. Cheat Sheet(Thu, Jun 13)
- Northwest Biotherapeutics: Targeting Glioblastoma With Immunotherapyat Seeking Alpha(Thu, Jun 13)
- Northwest Bio: M.D. Anderson's Lead Role In DC Vax Direct Trial Is Encouragingat Seeking Alpha(Thu, Jun 13)
- RedChip TV Announces Guest Lineup for This Week's "RedChip Money Report"GlobeNewswire(Thu, Jun 13)
- Northwest Biotherapeutics initiates DCVax-Direct Phase I/II trialtheflyonthewall.com(Thu, Jun 13)
- NW Bio Has Initiated Its DCVax®-Direct Phase I/II Trial For All Solid Tumor CancersPR Newswire(Thu, Jun 13)
- NW Bio's Dr. Marnix Bosch To Present At Brain Tumor Biotech Summit In New YorkPR Newswire(Thu, Jun 6)
- NW Bio Added To The MSCI Global MicroCap IndexPR Newswire(Mon, Jun 3)
- DelMar Pharmaceuticals To Present Updated Phase I GBM Data At ASCOat Seeking Alpha(Thu, May 30)
- NW Bio To Present Company Highlights At The Marcum MicroCap Conference In New YorkPR Newswire(Tue, May 28)
- NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 28)
- SmithOnStocks Opines On Biotechnology Stocks, May 24, 2013at Seeking Alpha(Mon, May 27)
- NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 118.57 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States.
View More 
1.35%